Get to know Radiation Oncologist Dr. Charles B. Simone, II, who serves patients in New York, New York


Charles B. Simone II, MD, FACRO, a Radiation Oncologist with the New York Proton Center & Memorial Sloan Kettering Cancer Center

(ProNewsReport Editorial):- New York City, New York Apr 20, 2021 ( – Dr. Simone is a Research Professor and the Chief Medical Officer of the New York Proton Center (NYPC) in New York City. It is the only facility in the state to offer proton radiation therapy, a highly advanced form of treatment that can reduce side effects and improve outcomes for cancer patients.

He is also a Full Member of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSK), and he works closely with the multidisciplinary thoracic cancer teams of NYPC’s three hospital partners – MSK, Mount Sinai Health System, and Montefiore Health System. 

Dr. Simone is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy. He is a National Institutes of Health, National Science Foundation, and Department of Defense-funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for lung cancer, malignant pleural mesothelioma, and other thoracic malignancies.

Previously, Dr. Simone was Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Director of the Penn Mesothelioma and Pleural Program, and Director of Clinical Research and Operations in the Department of Radiation Oncology at Penn. He was then appointed Medical Director of the Maryland Proton Treatment Center, and at the University of Maryland, he also served as Chair of the Clinical Research Committee for their Comprehensive Cancer Center, Proton Therapy Fellowship Director, and Director of the Stereotactic Radiation Therapy Program.  

Graduating with his Bachelor of Arts degree from the University of Pennsylvania in 2002, Dr. Simone went on to embark on his medical journey. He obtained his medical degree from the Perelman School of Medicine at the University of Pennsylvania in 2006. He then completed his internship in internal medicine and his residency in radiation oncology at the National Cancer Institute, National Institutes of Health, where he served as Chief Resident.

Achieving Diplomate status, he is board-certified through the American Board of Radiology (ABR). The mission of the ABR is to serve patients, the public, and the medical profession by certifying that its diplomates have acquired, demonstrated, and maintained a requisite standard of knowledge, skill, and understanding essential to the safe and competent practice of diagnostic radiology, radiation oncology, and medical physics.

After years of dedication and service to the American College of Radiation Oncology, Dr. Simone has been named a Fellow of the ACRO, recognizing his highly valued contributions to the College and to the greater field of oncology.

In addition, he is a member of the American Society for Radiation Oncology, the American Radium Society, the Particle Therapy Co-Operative Group, the Proton Collaborative Group, NRG Oncology, the International Mesothelioma Interest Group, the International Thymic Malignancy Interest Group, the Radiosurgical Society, the American Society of Clinical Oncology, and other multidisciplinary oncology societies. 

Radiation oncology is a medical specialty that involves the controlled use of radiation to treat cancer. It is one of the three primary specialties – the other two being surgical and medical oncology – involved in the treatment of cancer. A radiation oncologist is a specialist physician who uses ionizing radiation in the treatment of cancer.

Dr. Simone has published over 390 peer-reviewed scientific articles and book chapters, and he has given more than 245 scientific lectures to national and international audiences. He is also the Editor-in-Chief of the Annals of Palliative Medicine and on the Editorial Boards of Journal of Clinical Oncology, Cancers, Journal of Thoracic Disease, Frontiers in Oncology, Translational Lung Cancer Research, Annals of Translational Medicine, and Therapeutic Radiology and Oncology.

The national Principal Investigator or Co-Chair of 7 NIH-funded cooperative group trials, Dr. Simone is also a three-time winner of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award, and he is the Proton Collaborative Group (PCG) President of the Board of Directors.  He Chairs or Co-Chairs the PCG Executive Committee; PCG Lung Committee; American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee; ASTRO Small Cell Lung Cancer Guidelines Committee; American Radium Society-American College of Radiology (ARS-ACR) Appropriate Use Criteria Thoracic Committee; Particle Therapy Co-Operative Group (PTCOG) Gastrointestinal Subcommittee; PTCOG Skull Base/Central Nervous System, Sarcoma Subcommittee; American College of Radiation Oncology (ACRO) Recruitment Subcommittee; ACRO Annual Meeting Abstracts Committee; and National Cancer Institute/Radiosurgery Society (RSS) GRID-Lattice-Microbeam-Flash Radiotherapy Clinical Working Group.  

On a more personal note, Dr. Simone attributes his success to having great mentors and family support and being able to help his patients and follow their care over time.

Learn More about Dr. Charles B. Simone, II:
Through his findatopdoc profile,, through the New York Proton Center, or through Memorial Sloan Kettering Cancer Center, 

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Media Contact

Your Health Contact


Your Health Contact
Source :Charles B. Simone II, MD, FACRO

This article was originally published by IssueWire. Read the original article here.

More on the Pronewsreport: